A 4-gene expression score associated with high levels ofWilms Tumor-1 (WT1)expression is an adverse prognostic factor in acute myeloid leukaemia

Development of gene expression-based risk score in cytogenetically normal acute myeloid leukemia patients

(2015) Elias Bou Samra et al.   Oncotarget

Isolated trisomy 13 defines a homogeneous AML subgroup with high frequency of mutations in spliceosome genes and poor prognosis

(2014) T. Herold et al.   BLOOD

Comparison of RNA-Seq and Microarray in Transcriptome Profiling of Activated T Cells

(2014) Shanrong Zhao et al.   PLoS One

Identification of a 24-Gene Prognostic Signature That Improves the European LeukemiaNet Risk Classification of Acute Myeloid Leukemia: An International Collaborative Study

(2013) Zejuan Li et al.   JOURNAL OF CLINICAL ONCOLOGY

Epigenetics Meets Genetics in Acute Myeloid Leukemia: Clinical Impact of a Novel Seven-Gene Score

(2013) Guido Marcucci et al.   JOURNAL OF CLINICAL ONCOLOGY

Leukemia associated mutant Wilms’ tumor gene 1 protein promotes expansion of human hematopoietic progenitor cells

(2013) Karina Vidovic et al.   LEUKEMIA RESEARCH

Genomic and Epigenomic Landscapes of Adult De Novo Acute Myeloid Leukemia

(2013)   NEW ENGLAND JOURNAL OF MEDICINE

Comprehensive evaluation of differential gene expression analysis methods for RNA-seq data

(2013) Franck Rapaport et al.   GENOME BIOLOGY

High VEGFC expression is associated with unique gene expression profiles and predicts adverse prognosis in pediatric and adult acute myeloid leukemia

(2010) H. J. M. de Jonge et al.   BLOOD

Mutations of the Wilms tumor 1 gene (WT1) in older patients with primary cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B study

(2010) H. Becker et al.   BLOOD

Association of a Leukemic Stem Cell Gene Expression Signature With Clinical Outcomes in Acute Myeloid Leukemia

(2010) Andrew J. Gentles   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Novel histone deacetylase inhibitors in clinical trials as anti-cancer agents

(2010) Jiahuai Tan et al.   Journal of Hematology & Oncology

Prognostic impact ofWT1mutations in cytogenetically normal acute myeloid leukemia: a study of the German-Austrian AML Study Group

(2009) Verena Ingeborg Gaidzik et al.   BLOOD

Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet

(2009) H. Dohner et al.   BLOOD

Double CEBPA mutations, but not single CEBPA mutations, define a subgroup of acute myeloid leukemia with a distinctive gene expression profile that is uniquely associated with a favorable outcome

(2009) B. J. Wouters et al.   BLOOD

HighWT1gene expression before haematopoietic stem cell transplant in children with acute myeloid leukaemia predicts poor event-free survival

(2009) David A. Jacobsohn et al.   BRITISH JOURNAL OF HAEMATOLOGY

An integrated genome screen identifies the Wnt signaling pathway as a major target of WT1

(2009) M. K.-H. Kim et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

An 86-probe-set gene-expression signature predicts survival in cytogenetically normal acute myeloid leukemia

(2008) K. H. Metzeler et al.   BLOOD

High-affinity neurotrophin receptors and ligands promote leukemogenesis

(2008) Z. Li et al.   BLOOD

Prediction of molecular subtypes in acute myeloid leukemia based on gene expression profiling

(2008) R. G.W. Verhaak et al.   HAEMATOLOGICA

Mutation of the Wilms’ Tumor 1 Gene Is a Poor Prognostic Factor Associated With Chemotherapy Resistance in Normal Karyotype Acute Myeloid Leukemia: The United Kingdom Medical Research Council Adult Leukaemia Working Party

(2008) Priya Virappane et al.   JOURNAL OF CLINICAL ONCOLOGY